Amylyx Pharmaceuticals, Inc.
- Open
- 17.84
- Day high
- 18.05
- Day low
- 17.39
- Prev close
- 17.96
- Volume
- 1.3M
- Mkt cap
- $2.0B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 7.3
- P/S
- —
- Yield
- —
- Per share
- —
- ▲Insiders net buying $51K over the last 3 months (1 open-market buy, 0 sales)
- 🏛Institutions accumulating (13F)
Amylyx Pharmaceuticals, Inc. (AMLX) is a Healthcare company listed on NASDAQ. The stock is up 180% over the past year. Over the trailing 3 months, insiders filed 1 open-market buy and 0 sales (SEC Form 4).
Amylyx Pharmaceuticals, Inc. (AMLX) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
AMLX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-0.34 | $-0.37 | -8.8% | — | — |
| Mar 3, 2026 | $-0.31 | $-0.30 | +3.2% | — | — |
| Nov 6, 2025 | $-0.43 | $-0.37 | +14.0% | — | — |
| Aug 7, 2025 | $-0.44 | $-0.46 | -4.5% | — | — |
| May 8, 2025 | $-0.45 | $-0.42 | +6.7% | — | — |
| Mar 4, 2025 | $-0.49 | $-0.55 | -12.2% | $665000 | — |
| Nov 7, 2024 | $-0.47 | $-0.53 | -12.8% | $416000 | — |
| Aug 8, 2024 | $-0.38 | $-0.73 | -92.1% | $1M | -90.4% |
| May 9, 2024 | $0.24 | $-0.46 | -291.7% | $89M | -9.9% |
| Feb 22, 2024 | $0.23 | $0.07 | -69.6% | $108M | +1.4% |
| Nov 9, 2023 | $0.44 | $0.30 | -31.8% | $103M | -4.8% |
| Aug 10, 2023 | $0.10 | $0.31 | +210.0% | $98M | +6.6% |
AMLX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 8, 2026 | Quimi Daphnedirector | Grant | 24,372 | $14.31 |
| Jun 8, 2026 | MILNE GEORGE M JRdirector | Grant | 24,372 | $14.31 |
| Jun 8, 2026 | FONTEYNE PAUL R.director | Grant | 24,372 | $14.31 |
| Jun 8, 2026 | Zeiher Bernhardt Gdirector | Grant | 24,372 | $14.31 |
| Jun 8, 2026 | Firestone Karendirector | Grant | 24,372 | $14.31 |
| May 26, 2026 | Firestone Karendirector | Buy | 3,800 | $13.51 |
| Mar 9, 2026 | Cohen Joshua Bdirector, officer: Co-Chief Executive Officer | Grant | 248,865 | — |
| Mar 9, 2026 | Klee Justin B.director, officer: Co-Chief Executive Officer | Grant | 248,865 | — |
| Mar 9, 2026 | FRATES JAMES Mofficer: Chief Financial Officer | Grant | 143,985 | $14.10 |
| Mar 9, 2026 | FRATES JAMES Mofficer: Chief Financial Officer | Grant | 95,990 | — |
| Mar 9, 2026 | Mazzariello Ginaofficer: Chief Legal Officer | Grant | 111,990 | $14.10 |
| Mar 9, 2026 | Mazzariello Ginaofficer: Chief Legal Officer | Grant | 74,660 | — |
| Mar 9, 2026 | Cohen Joshua Bdirector, officer: Co-Chief Executive Officer | Grant | 373,295 | $14.10 |
| Mar 9, 2026 | Bedrosian Camille Lofficer: Chief Medical Officer | Grant | 143,985 | $14.10 |
| Mar 9, 2026 | Bedrosian Camille Lofficer: Chief Medical Officer | Grant | 95,990 | — |
Source: AMLX SEC Form 4 filings, latest Jun 8, 2026. For informational purposes only — not investment advice.
See the full AMLX insider & 13F page →Amylyx Pharmaceuticals, Inc. company profile
Overview
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Cambridge, Massachusetts. The company went public in January 2022 and initially gained prominence with its ALS drug RELYVRIO, which received FDA approval in September 2022. However, following disappointing Phase 3 trial results, Amylyx voluntarily withdrew RELYVRIO from the market in April 2024. The company has since pivoted to focus on developing treatments for rare neurodegenerative and endocrine disorders, with its lead asset avexitide targeting post-bariatric hypoglycemia.
Business
Amylyx operates in the biotechnology sector, specifically developing therapeutics for rare neurodegenerative and endocrine diseases. The company's approach centers on mechanism-driven drug development, targeting specific biological pathways involved in disease progression. The company's current pipeline consists of four main programs: 1. Avexitide for Post-Bariatric Hypoglycemia (PBH) - This is the company's lead asset, a GLP-1 receptor antagonist designed to treat severe low blood sugar episodes that occur in some patients following bariatric (weight loss) surgery. Post-bariatric hypoglycemia affects approximately 160,000 patients in the US who experience dangerous drops in blood glucose levels after eating, which can lead to seizures, loss of consciousness, and other serious complications. Avexitide works by blocking GLP-1 receptors to reduce excessive insulin release. 2. AMX0035 for Wolfram Syndrome - This program repurposes the company's original ALS compound for Wolfram syndrome, a rare genetic disorder that causes diabetes and progressive vision loss. The drug is designed to protect cells from stress-induced death by targeting two cellular pathways: the unfolded protein response and mitochondrial-mediated apoptosis. 3. AMX0035 for Progressive Supranuclear Palsy (PSP) - The same compound is being tested for PSP, a rare brain disorder that causes problems with walking, balance, and eye movements. The treatment aims to reduce tau protein accumulation in the brain, which is believed to drive disease progression. 4. AMX0114 for ALS - This is an antisense oligonucleotide (a type of genetic medicine) that targets the CAPN2 gene to reduce production of calpain-2 protein, which may contribute to nerve cell death in amyotrophic lateral sclerosis. The company estimates that avexitide represents the largest commercial opportunity, targeting a market of 160,000 patients with limited treatment options.
Revenue model
Amylyx's business model is built around developing and commercializing prescription drugs for rare diseases, generating revenue through product sales to patients via healthcare providers and pharmacies. The company's customers are primarily physicians who prescribe the treatments and patients who use them, with revenue flowing through the typical pharmaceutical distribution chain including wholesalers, specialty pharmacies, and insurance payers. The company previously demonstrated this model with RELYVRIO, which generated $380.8 million in revenue during 2023 before being withdrawn from the market. The drug was priced as a premium orphan therapy, with gross-to-net price adjustments of approximately 12-14% due to insurance rebates and patient assistance programs. Several factors significantly impact the company's margins and commercial prospects: Positive margin drivers include the orphan drug designation for most of its pipeline, which provides market exclusivity and premium pricing opportunities. The company's focus on rare diseases with limited treatment alternatives allows for higher pricing power. Additionally, breakthrough therapy designations (like avexitide has received) can accelerate regulatory approval and market entry. Negative margin pressures come from the high costs of clinical development, particularly Phase 3 trials which can cost tens of millions of dollars. The company faces ongoing R&D expenses of $20-25 million per quarter and SG&A costs of $15-20 million quarterly. Insurance negotiations and prior authorization requirements can limit patient access and reduce effective pricing. The small patient populations in rare diseases also limit total addressable market size, requiring high per-patient pricing to achieve commercial viability. The company's success depends heavily on clinical trial outcomes, regulatory approvals, and the ability to achieve adequate pricing and reimbursement from insurance payers. Market competition from larger pharmaceutical companies developing treatments for the same conditions could also pressure margins and market share.
Competitive moat
Amylyx's competitive positioning is relatively weak, with limited sustainable competitive advantages. The company's primary assets are regulatory exclusivity periods from orphan drug designations, which provide 7 years of market exclusivity in the US for approved treatments. However, these protections are temporary and do not prevent competitors from developing alternative treatments targeting the same diseases through different mechanisms. The company's scientific expertise in neurodegenerative disease mechanisms provides some differentiation, particularly its dual-pathway approach targeting both cellular stress responses and mitochondrial dysfunction. The management team's experience navigating rare disease drug development and commercialization, demonstrated through the RELYVRIO launch, represents institutional knowledge that has value. However, several factors limit the strength of these competitive advantages. The company lacks significant intellectual property barriers, as most of its compounds are repurposed existing molecules rather than novel chemical entities. Amylyx faces potential competition from well-capitalized pharmaceutical giants like Roche, Novartis, and Biogen, which have substantially greater resources for R&D and commercialization. The failure of RELYVRIO in Phase 3 trials also damaged the company's credibility and scientific reputation. For avexitide specifically, the company benefits from being potentially first-to-market in post-bariatric hypoglycemia, but this advantage could be temporary if larger competitors develop competing treatments. The relatively small patient populations in the company's target markets make them attractive acquisition targets for larger companies seeking to build rare disease portfolios. Overall, Amylyx operates in a challenging competitive environment where success depends primarily on execution of clinical trials and regulatory approvals rather than sustainable competitive moats. The company's survival likely depends on achieving positive clinical results and either successful commercialization or acquisition by a larger pharmaceutical company.
Risks & safety
The company presents a moderate margin of safety profile, with sufficient cash reserves but ongoing losses and execution risks. • Liquidity position: Strong cash position of $204.1 million as of Q1 2025, providing runway through end of 2026 at current burn rates of approximately $40 million per quarter • Debt levels: Minimal debt with debt-to-equity ratio of 0.007, eliminating solvency risk from leverage • Burn rate: Free cash flow burn of approximately $40 million quarterly, down significantly from prior periods due to cost reduction efforts • Current ratio: Excellent liquidity with current ratio of 12.1, indicating strong ability to meet short-term obligations • Valuation metrics: Trading at 1.5x book value and negative P/E due to losses; Graham net-net ratio of 2.2 suggests potential asset-based value • Revenue risk: Currently pre-revenue after RELYVRIO withdrawal, making the company entirely dependent on clinical trial success for future cash generation • Binary risk profile: Success heavily dependent on avexitide Phase 3 trial results expected in 2026, creating significant execution risk concentrated in single asset
Recent development
Over the past two years, Amylyx has undergone a dramatic strategic transformation following the failure of its lead ALS drug RELYVRIO. The company initially achieved commercial success with RELYVRIO, generating $380.8 million in revenue during 2023 and reaching profitability. However, disappointing results from the Phase 3 PHOENIX trial led to the voluntary withdrawal of RELYVRIO from global markets in April 2024, eliminating the company's primary revenue source. In response to this setback, Amylyx executed a comprehensive strategic pivot focused on portfolio diversification and cost optimization. The company reduced operating expenses by over 80% from 2024 levels, cutting quarterly burn from over $100 million to approximately $40 million. Management streamlined operations while maintaining four distinct clinical programs targeting different rare diseases. The company's new strategic focus centers on avexitide as the lead commercial asset, with management prioritizing this program for post-bariatric hypoglycemia. Avexitide received breakthrough therapy designation from the FDA and is advancing toward a Phase 3 trial launching in Q1 2025. The company has also appointed Dan Monahan as Chief Commercial Officer to prepare for potential commercialization. Simultaneously, Amylyx has pursued life cycle management of its AMX0035 compound by exploring applications in Wolfram syndrome and progressive supranuclear palsy. The Wolfram syndrome program showed positive Phase 2 results, while the PSP program is expected to provide interim data in Q3 2025. The company has also initiated development of AMX0114, a novel antisense oligonucleotide for ALS, representing a new approach to treating the disease that originally brought the company to prominence. To support this expanded pipeline, Amylyx raised $65.5 million in additional financing during late 2024, extending its cash runway through 2026. The company has also established a collaboration with Gubra to develop long-acting GLP-1 receptor antagonists, potentially expanding the avexitide franchise beyond its initial indication.
AMLX company profile · for informational purposes only — not investment advice.
Track AMLX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free